Comparing two psoriasis medications in adults over 70
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study compares two biologic medications, ixekizumab and secukinumab, to see which works better for psoriasis in people aged 70 and older. Both drugs are given as injections and aim to reduce skin symptoms and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 70 years old or older.
- You need to have had psoriasis for at least 6 months.
- Your psoriasis must cover at least 3% of your body (about three palm-sized areas) or cause major impact on daily life.
- You should be a candidate for biologic therapy (medications that target the immune system).
- You must not have had certain other systemic treatments (like methotrexate or cyclosporine) in the past 4 weeks.
- You cannot have serious infections (like tuberculosis, HIV, hepatitis B or C) or other major conditions like inflammatory bowel disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well ixekizumab (an injection medication) works for moderate-to-severe plaque psoriasis, and what happens when the treatment is withdrawn. It may help you learn whether stopping the medicine is safe and how skin disease outcomes change over time.
This study tests how well a biologic medication works and what happens when it is stopped in adults with moderate-to-severe plaque psoriasis. It may help you find a treatment that controls your symptoms and also informs you about managing your condition.
This study compares a proactive approach (adjusting drug levels based on regular blood tests) versus the usual way of using biologics for psoriasis. It helps see if active monitoring can improve treatment while keeping you safe.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
This study looks at immune system differences in people with moderate-to-severe psoriasis. It aims to help guide more precise (targeted) treatment choices and may improve how well treatment works for you.
This trial tests an investigational drug, HB0017, in adults with moderate to severe plaque psoriasis. If you have had psoriasis for at least 6 months and have not used certain biologic treatments, you may be able to join.
Hear when a new Over 70-year-old Patients with Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.